HighTower Advisors’s VanEck Biotech ETF BBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $878K | Sell |
4,669
-1,912
| -29% | -$368K | ﹤0.01% | 2279 |
|
|
2025
Q4 | $1.25M | Sell |
6,581
-11
| -0.2% | -$2.04K | ﹤0.01% | 1973 |
|
|
2025
Q3 | $1.09M | Sell |
6,592
-3,030
| -31% | -$494K | ﹤0.01% | 2034 |
|
|
2025
Q2 | $1.47M | Sell |
9,622
-236
| -2% | -$35.1K | ﹤0.01% | 1756 |
|
|
2025
Q1 | $1.55M | Sell |
9,858
-45
| -0.5% | -$7.3K | ﹤0.01% | 1666 |
|
|
2024
Q4 | $1.55M | Buy |
9,903
+1,058
| +12% | +$178K | ﹤0.01% | 1670 |
|
|
2024
Q3 | $1.57M | Sell |
8,845
-168
| -2% | -$29.8K | ﹤0.01% | 1657 |
|
|
2024
Q2 | $1.52M | Buy |
9,013
+201
| +2% | +$32.9K | ﹤0.01% | 1604 |
|
|
2024
Q1 | $1.46M | Sell |
8,812
-689
| -7% | -$114K | ﹤0.01% | 1585 |
|
|
2023
Q4 | $1.57M | Sell |
9,501
-207
| -2% | -$31.9K | ﹤0.01% | 1573 |
|
|
2023
Q3 | $1.52M | Hold |
9,708
| – | – | ﹤0.01% | 1537 |
|
|
2023
Q2 | $1.52M | Buy |
9,708
+433
| +5% | +$69.2K | ﹤0.01% | 1515 |
|
|
2023
Q1 | $1.5M | Hold |
9,275
| – | – | ﹤0.01% | 1450 |
|
|
2022
Q4 | $1.48M | Sell |
9,275
-18
| -0.2% | -$2.85K | ﹤0.01% | 1447 |
|
|
2022
Q3 | $1.31M | Buy |
9,293
+90
| +1% | +$13.6K | ﹤0.01% | 1464 |
|
|
2022
Q2 | $1.34M | Sell |
9,203
-2,257
| -20% | -$336K | ﹤0.01% | 1478 |
|
|
2022
Q1 | $1.86M | Sell |
11,460
-2,008
| -15% | -$325K | ﹤0.01% | 1419 |
|
|
2021
Q4 | $2.55M | Buy |
13,468
+1,081
| +9% | +$208K | 0.01% | 1224 |
|
|
2021
Q3 | $2.51M | Buy |
12,387
+1,628
| +15% | +$342K | 0.01% | 1139 |
|
|
2021
Q2 | $2.17M | Buy |
10,759
+214
| +2% | +$39.8K | 0.01% | 1176 |
|
|
2021
Q1 | $1.85M | Buy |
+10,545
| New | +$1.91M | 0.01% | 1169 |
|
|
2020
Q4 | – | Sell |
-13,642
| Closed | -$2.21M | – | 2608 |
|
|
2020
Q3 | $2.21M | Sell |
13,642
-998
| -7% | -$162K | 0.01% | 843 |
|
|
2020
Q2 | $2.38M | Buy |
14,640
+541
| +4% | +$82.2K | 0.01% | 740 |
|
|
2020
Q1 | $1.81M | Buy |
14,099
+1,477
| +12% | +$199K | 0.01% | 779 |
|
|
2019
Q4 | $1.76M | Buy |
12,622
+10
| +0.1% | +$1.31K | 0.01% | 904 |
|
|
2019
Q3 | $1.49M | Sell |
12,612
-300
| -2% | -$37.3K | 0.01% | 991 |
|
|
2019
Q2 | $1.66M | Sell |
12,912
-120
| -0.9% | -$14.8K | 0.01% | 973 |
|
|
2019
Q1 | $1.67M | Buy |
13,032
+162
| +1% | +$20.5K | 0.01% | 927 |
|
|
2018
Q4 | $1.42M | Sell |
12,870
-2,575
| -17% | -$311K | 0.01% | 901 |
|
|
2018
Q3 | $2.1M | Buy |
15,445
+1,526
| +11% | +$198K | 0.02% | 812 |
|
|
2018
Q2 | $1.67M | Sell |
13,919
-289
| -2% | -$34.1K | 0.01% | 914 |
|
|
2018
Q1 | $1.71M | Sell |
14,208
-139
| -1% | -$17.4K | 0.01% | 864 |
|
|
2017
Q4 | $1.79M | Buy |
14,347
+667
| +5% | +$85.2K | 0.01% | 861 |
|
|
2017
Q3 | $1.83M | Buy |
13,680
+724
| +6% | +$94.3K | 0.02% | 852 |
|
|
2017
Q2 | $1.63M | Buy |
12,956
+1,036
| +9% | +$125K | 0.01% | 878 |
|
|
2017
Q1 | $1.42M | Sell |
11,920
-14,313
| -55% | -$1.67M | 0.01% | 880 |
|
|
2016
Q4 | $2.82M | Buy |
26,233
+15,332
| +141% | +$1.67M | 0.03% | 584 |
|
|
2016
Q3 | $1.26M | Buy |
10,901
+230
| +2% | +$26.2K | 0.01% | 832 |
|
|
2016
Q2 | $1.09M | Buy |
+10,671
| New | +$1.14M | 0.01% | 844 |
|
|
2016
Q1 | – | Sell |
-4,945
| Closed | -$627K | – | 2072 |
|
|
2015
Q4 | $627K | Sell |
4,945
-474
| -9% | -$58.1K | 0.01% | 1202 |
|
|
2015
Q3 | $618K | Sell |
5,419
-700
| -11% | -$92.7K | 0.01% | 1113 |
|
|
2015
Q2 | $825K | Buy |
6,119
+800
| +15% | +$106K | 0.01% | 840 |
|
|
2015
Q1 | $689K | Buy |
5,319
+700
| +15% | +$88K | 0.01% | 952 |
|
|
2014
Q4 | $533K | Sell |
4,619
-4
| -0.1% | -$451 | 0.01% | 1028 |
|
|
2014
Q3 | $489K | Buy |
4,623
+23
| +0.5% | +$2.33K | 0.01% | 1029 |
|
|
2014
Q2 | $439K | Buy |
+4,600
| New | +$412K | 0.01% | 1093 |
|
Other funds holding BBH
MIM
CCA
BFG
HighTower Advisors's BBH Position: Q1 2026 in Review
HighTower Advisors reduced its VanEck Biotech ETF (BBH) stake by 29% in Q1 2026, selling an estimated $368K and leaving 4,669 shares worth $878K. The position accounts for ﹤0.01% of the portfolio, ranked #2279.
HighTower Advisors first reported a position in BBH in Q2 2014 and has held it in 46 quarters since. The position peaked at $2.82M in Q4 2016. 112 funds tracked by Wall St. Rank hold BBH as of Q1 2026.
- HighTower Advisors held 4,669 shares of VanEck Biotech ETF worth $878K as of Q1 2026.
- HighTower Advisors sold 1,912 VanEck Biotech ETF shares in Q1 2026, an estimated $368K.
- VanEck Biotech ETF made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #2279 holding.
- HighTower Advisors first reported a position in VanEck Biotech ETF in Q2 2014 and has held it in 46 quarters since.
- HighTower Advisors's VanEck Biotech ETF position peaked at $2.82M in Q4 2016.
- 112 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2026.
Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.